Pipeline

4 “first-in-class” products to reduce the risk of metabolic diseases

VALBIOTIS aims to revolutionize healthcare by developing a new class of products designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
These innovative products are designed for people at risk of developing type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and/or cardiovascular diseases.
Clinical development plans are in place to obtain specific health claims for each product, recognized by regulatory authorities such as the FDA (Food and Drug Administration, the United States) and the EFSA (European Food Safety Authority, Europe).

Our pipeline

Key figures

VALEDIA®

400

people in total will be included in the clinical development plan for VALEDIA®.

INTELLECTUAL PROPERTY

4

patent families and a global protection strategy.

CLINICAL STUDIES

9

3 studies already completed, 1 study currently underway, 5 studies which should be launched in 2019.

REGULATORY AUTHORITIES

3

areas will be targeted as a priority: the United States (FDA), Canada (Santé Canada) and Europe (EFSA).